FDA panel to focus on safety of Novartis gene therapy drug – WHTC
WHTC |
FDA panel to focus on safety of Novartis gene therapy drug
WHTC (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug when it meets to review the leukemia treatment on Wednesday. The keenly anticipated preliminary review … |
Business Insider |
FDA panel to focus on safety of Novartis gene therapy drug …
Business Insider (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug when it … Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network |
Genetic Literacy Project |
NY Times’ Carl Zimmer: CRISPR gene editing vital but offers ethical challenges
Genetic Literacy Project [Editor’s Note: Carl Zimmer is a columnist at the New York Times, where his column “Matter” appears each week. He has written books, articles, and essays about the frontiers of biology and how scientists are making efforts to expand our understanding … |
|
Broad Institute of MIT and Harvard Joins Discussions to Create Worldwide CRISPR-Cas9 Licensing Pool
SYS-CON Media (press release) CAMBRIDGE, Mass., July 10, 2017 /PRNewswire/ — Seeking new opportunities to make CRISPR genome editing technology widely available, the Broad Institute of MIT and Harvard has joined discussions to create a non-exclusive CRISPR-Cas9 joint … The Broad Institute of MIT and Harvard Among Those Participating in MPEG LA’s CRISPR-Cas9 Joint Licensing …Digital Journal (press release) |